Caplin Point Laboratories Future Growth
Future criteria checks 2/6
Caplin Point Laboratories is forecast to grow earnings and revenue by 13.6% and 13.2% per annum respectively. EPS is expected to grow by 13.6% per annum. Return on equity is forecast to be 18.6% in 3 years.
Key information
13.6%
Earnings growth rate
13.6%
EPS growth rate
| Pharmaceuticals earnings growth | 17.8% |
| Revenue growth rate | 13.2% |
| Future return on equity | 18.6% |
| Analyst coverage | Low |
| Last updated | 11 Nov 2024 |
Recent future growth updates
₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results
Nov 10
Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764
Aug 11Recent updates
₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results
Nov 10With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 31Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50
Sep 12Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764
Aug 11Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50
Aug 10Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings
Jul 12Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues
May 24Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?
May 04Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement
Mar 07With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 24Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise
Sep 15Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50
Aug 11We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise
Sep 23Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year
Sep 11Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?
Jul 22Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00
May 15A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Jan 21Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Oct 20Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50
Sep 17Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50
Sep 03Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price
Aug 27Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?
Jun 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 25,604 | 7,061 | 5,040 | 5,119 | 1 |
| 3/31/2026 | 22,369 | 5,806 | 4,138 | 5,220 | 3 |
| 3/31/2025 | 19,665 | 5,069 | 3,174 | 4,027 | 3 |
| 9/30/2024 | 18,328 | 4,936 | 2,310 | 3,748 | N/A |
| 6/30/2024 | 17,577 | 4,776 | N/A | N/A | N/A |
| 3/31/2024 | 16,961 | 4,571 | 1,726 | 3,184 | N/A |
| 12/31/2023 | 16,318 | 4,376 | N/A | N/A | N/A |
| 9/30/2023 | 15,683 | 4,179 | 399 | 2,593 | N/A |
| 6/30/2023 | 15,157 | 3,947 | N/A | N/A | N/A |
| 3/31/2023 | 14,683 | 3,763 | 779 | 2,714 | N/A |
| 12/31/2022 | 14,182 | 3,532 | N/A | N/A | N/A |
| 9/30/2022 | 13,724 | 3,307 | 2,305 | 3,467 | N/A |
| 6/30/2022 | 13,153 | 3,140 | N/A | N/A | N/A |
| 3/31/2022 | 12,710 | 2,998 | 2,456 | 3,367 | N/A |
| 12/31/2021 | 12,099 | 2,872 | N/A | N/A | N/A |
| 9/30/2021 | 11,581 | 2,767 | 1,288 | 2,044 | N/A |
| 6/30/2021 | 11,217 | 2,586 | N/A | N/A | N/A |
| 3/31/2021 | 10,624 | 2,423 | 1,953 | 2,686 | N/A |
| 12/31/2020 | 9,986 | 2,248 | N/A | N/A | N/A |
| 9/30/2020 | 9,524 | 2,189 | 1,650 | 1,877 | N/A |
| 6/30/2020 | 9,107 | 2,193 | N/A | N/A | N/A |
| 3/31/2020 | 8,640 | 2,150 | -321 | 447 | N/A |
| 12/31/2019 | 8,356 | 2,159 | N/A | N/A | N/A |
| 9/30/2019 | 7,664 | 2,032 | -331 | 830 | N/A |
| 6/30/2019 | 6,948 | 1,894 | N/A | N/A | N/A |
| 3/31/2019 | 6,490 | 1,766 | 182 | 834 | N/A |
| 12/31/2018 | 6,048 | 1,621 | N/A | N/A | N/A |
| 9/30/2018 | 5,874 | 1,538 | N/A | N/A | N/A |
| 6/30/2018 | 5,628 | 1,459 | N/A | N/A | N/A |
| 3/31/2018 | 5,399 | 1,448 | N/A | 665 | N/A |
| 12/31/2017 | 5,145 | 1,430 | N/A | N/A | N/A |
| 9/30/2017 | 4,757 | 1,297 | N/A | N/A | N/A |
| 6/30/2017 | 4,401 | 1,165 | N/A | N/A | N/A |
| 3/31/2017 | 4,016 | 956 | N/A | 676 | N/A |
| 12/31/2016 | 3,655 | 783 | N/A | N/A | N/A |
| 9/30/2016 | 3,420 | 703 | N/A | N/A | N/A |
| 6/30/2016 | 3,238 | 619 | N/A | N/A | N/A |
| 3/31/2016 | 3,088 | 584 | N/A | 565 | N/A |
| 12/31/2015 | 2,906 | 535 | N/A | N/A | N/A |
| 9/30/2015 | 2,722 | 465 | N/A | N/A | N/A |
| 6/30/2015 | 2,518 | 410 | N/A | 499 | N/A |
| 3/31/2015 | 2,296 | 353 | N/A | N/A | N/A |
| 12/31/2014 | 2,074 | 318 | N/A | N/A | N/A |
| 9/30/2014 | 1,893 | 305 | N/A | N/A | N/A |
| 6/30/2014 | 1,731 | 258 | N/A | 598 | N/A |
| 3/31/2014 | 1,643 | 204 | N/A | N/A | N/A |
| 12/31/2013 | 1,517 | 167 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CAPLIPOINT's forecast earnings growth (13.6% per year) is above the savings rate (6.7%).
Earnings vs Market: CAPLIPOINT's earnings (13.6% per year) are forecast to grow slower than the Indian market (18.1% per year).
High Growth Earnings: CAPLIPOINT's earnings are forecast to grow, but not significantly.
Revenue vs Market: CAPLIPOINT's revenue (13.2% per year) is forecast to grow faster than the Indian market (10.5% per year).
High Growth Revenue: CAPLIPOINT's revenue (13.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CAPLIPOINT's Return on Equity is forecast to be low in 3 years time (18.6%).